80
Participants
Start Date
November 20, 2023
Primary Completion Date
February 1, 2025
Study Completion Date
August 1, 2025
SGLT2i
A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
Messejana Hospital, Fortaleza
Hospital de Messejana
UNKNOWN
Universidade Federal do Ceara
OTHER